Molecular Staging
Transforming the Detection and Measurement of both Proteins and Nucleic Acids.
About us
A strong demand has emerged in the life science industry for enabling technologies that can generate, analyze, and interpret genomics and proteomics data much more quickly and cost effectively than currently possible otherwise.
Molecular Staging Inc. (MSI), a life sciences company, is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.
These technologies are transformational because there has never before been a powerful molecular amplification method for proteins, or an effective whole genome amplification method…and because the technology platform combines unprecedented sensitivity and multiplexing advantages. MSI technologies, combined with sophisticated bioinformatics, broadly enable a wide range of products and services across multiple health care markets.
These products and services include: High-coverage protein microarrays analogous to the DNA microarray, enabling researchers to study multiple proteins simultaneously.
Whole-genome amplification that allows DNA samples to be renewable resources, enabling researchers to return to them again and again for new tests or confirmatory diagnoses. Ultra-sensitive, multiplexed diagnostics that enable earlier detection of disease and reduced costs.
Technology
We plan to develop and commercialize gene-based tests and immunoassays based on our core technology, Rolling Circle Amplification Technology (RCAT™), that can significantly improve the diagnosis of cancer, infectious diseases, neuropsychiatric disorders, auto-immune disorders, and other major disease states.
How It Works:
In order to diagnose a disease, physicians often need to look for things that are small in size such as cancer cells, virus particles, bacteria, mutated genes, etc. Physicians will use tests to find “target molecules” associated with these diseased cells or pathogens that indicate their presence. These target molecules might be the DNA of a bacteria or virus, a protein produced by cancerous cells, antibodies to a particular infection, or a particular sequence of a gene mutation. These target molecules are often present at very low levels, particularly in early stages of the disease when treatment might be the most beneficial. Physicians need a test that can easily locate the molecule of interest, and then “amplify” a signal from that molecule to indicate its detection.
We are committed to advancing the field of molecular diagnostics by developing and commercializing gene-based tests and immunoassays utilizing Rolling Circle Amplification Technology (RCAT™). This powerful technology has the potential to significantly enhance the detection and diagnosis of cancer, infectious diseases, neuropsychiatric disorders, autoimmune disorders, and other major disease states.
How It Works
The early and accurate diagnosis of disease requires detecting minuscule biological markers—such as cancer cells, virus particles, bacteria, or mutated genes—that serve as indicators of pathological conditions. These markers, known as target molecules, can include:DNA or RNA sequences specific to a virus, bacterium, or genetic mutationProteins uniquely produced by cancerous or diseased cellsAntibodies that signal an immune response to infectionIn many cases, these target molecules are present in extremely low concentrations, especially in early disease stages, when treatment can be most effective. Traditional diagnostic methods often struggle with sensitivity, making early detection a challenge.RCAT™: Precision Amplification for Enhanced DetectionRCAT™ overcomes these limitations by amplifying the signal from even the smallest traces of a target molecule, making them easily detectable. This is achieved through a highly efficient and specific process of circular DNA replication, which generates billions of copies of the target signal in a short time. The result is a highly sensitive, rapid, and accurate detection method that can be applied across a wide range of diagnostic applications.By leveraging RCAT™, our goal is to redefine diagnostic accuracy, enabling earlier disease detection, improving patient outcomes, and facilitating the development of next-generation precision medicine.